

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Ultra-LEAF(TM) Purified anti-human CD28

RRID:AB_2616667

Type: Antibody

Proper Citation

BioLegend Cat# 302943, RRID:AB_2616667

Antibody Information

URL: http://antibodyregistry.org/AB_2616667

Proper Citation: BioLegend Cat# 302943, RRID:AB_2616667

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_2616667

Vendor: BioLegend

Catalog Number: 302943

Alternative Catalog Numbers: 302934, 302933, 302944, 302959, 302960

Record Creation Time: 20231110T034921+0000

Record Last Update: 20260831T204139+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Carp DM, et al. (2026) Single-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry. Cell reports methods, 6(4), 101343.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nature protocols, 20(5), 1352.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell reports, 44(1), 115156.

Kobiyama K, et al. (2025) Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox. EBioMedicine, 115, 105703.

Zhang S, et al. (2025) Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. Cancer cell, 43(8), 1423.

Lindner S, et al. (2024) Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. Nature microbiology, 9(3), 614.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. Cell reports. Medicine, 5(7), 101620.

Berger S, et al. (2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell, 187(16), 4305.

Wang Q, et al. (2024) The CARD8 inflammasome dictates HIV/SIV pathogenesis and disease progression. Cell, 187(5), 1223.

Lin CJ, et al. (2024) Genetic interactions reveal distinct biological and therapeutic implications in breast cancer. Cancer cell, 42(4), 701.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. Cell, 185(8), 1414.

Lötscher J, et al. (2022) Magnesium sensing via LFA-1 regulates CD8⁺ T cell effector function. *Cell*, 185(4), 585.

Glassman CR, et al. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. *Cell*, 184(4), 983.

Sadik A, et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, 182(5), 1252.

Grandclaude M, et al. (2019) A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication. *Cell*, 179(2), 432.